Risk of prostate cancer in relation to polymorphisms of metabolic genes

被引:25
作者
Chen, C [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
关键词
D O I
10.1093/oxfordjournals.epirev.a000793
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The study of associations between genetic polymorphisms of metabolic enzymes and prostate cancer risk can provide insight into the potential etiologic role of xenobiotics in prostate cancer development. To date there is little evidence that the incidence of prostate cancer is influenced by any of the genetic polymorphisms described above. However, the number of subjects studied generally has been small, so it would be premature to conclude that the substances metabolized by enzymes encoded by these candidate genes are not of carcinogenic importance, or to conclude that the polymorphisms of these genes do not play a role in prostate cancer susceptibility. Larger-scale studies of these and other genes, such as genes that repair cellular damage and regulate cell growth, are needed. Since gene-gene and gene-environment interactions may contribute to cancer risk, it would be desirable to conduct studies in which both biomarkers (or other measures) of exposure and polymorphisms of multiple genes are examined.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 86 条
  • [1] Expression in human prostate of drug- and carcinogen-metabolizing enzymes:: association with prostate cancer risk
    Agúndez, JAG
    Martínez, C
    Olivera, M
    Gallardo, L
    Ladero, JM
    Rosado, C
    Prados, J
    Rodriguez-Molina, J
    Resel, L
    Benítez, J
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (10) : 1361 - 1367
  • [2] AliOsman F, 1997, J BIOL CHEM, V272, P10004
  • [3] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 - Response
    Amirimani, B
    Walker, AH
    Weber, BL
    Rebbeck, TR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) : 1588 - 1590
  • [4] Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
    Ando, Y
    Tateishi, T
    Sekido, Y
    Yamamoto, T
    Satoh, T
    Hasegawa, Y
    Kobayashi, S
    Katsumata, Y
    Shimokata, K
    Saito, H
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (18) : 1587 - 1588
  • [5] Glutathione S-transferases as risk factors in prostate cancer
    Autrup, JLC
    Thomassen, LH
    Olsen, JH
    Wolf, H
    Autrup, H
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 1999, 8 (06) : 525 - 532
  • [6] Bailey LR, 1998, CANCER RES, V58, P65
  • [7] GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS
    BELL, DA
    TAYLOR, JA
    BUTLER, MA
    STEPHENS, EA
    WIEST, J
    BRUBAKER, LH
    KADLUBAR, FF
    LUCIER, GW
    [J]. CARCINOGENESIS, 1993, 14 (08) : 1689 - 1692
  • [8] MENDELIAN INHERITANCE OF FAMILIAL PROSTATE-CANCER
    CARTER, BS
    BEATY, TH
    STEINBERG, GD
    CHILDS, B
    WALSH, PC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) : 3367 - 3371
  • [9] Arylamine N-acetyltransferase activity in man
    Cascorbi, I
    Brockmöller, J
    Mrozikiewicz, PM
    Müller, A
    Roots, I
    [J]. DRUG METABOLISM REVIEWS, 1999, 31 (02) : 489 - 502
  • [10] Cascorbi I, 1996, CANCER RES, V56, P4965